Bronchiectasis Epidemiology Forecast - 2034
Description
Key Highlights
Bronchiectasis is a chronic lung disease marked by the permanent widening of the bronchial airways and impaired mucociliary function, resulting from repeated infections that promote bacterial invasion and mucus build up in the bronchial tree.
Bronchiectasis may develop due to various underlying lung-related conditions, including airway obstructions, cystic fibrosis, autoimmune and immunodeficiency disorders, chronic obstructive pulmonary disease (COPD), ciliary dysfunction, inflammatory bowel disease, allergic bronchopulmonary aspergillosis, chronic aspiration, and recurrent infections such as pneumonia, tuberculosis, pertussis, and fungal diseases.
In 2024, there were approximately 1,050,000 total diagnosed prevalent cases of non-cystic fibrosis bronchiectasis (NCFB) in the 7MM.
In 2024, there were approximately 79,000 total diagnosed prevalent cases of Cystic Fibrosis Bronchiectasis in the 7MM.
Among the 7MM, the US accounted for approximately 37%, EU4, and the UK for nearly 54%, and Japan for around 9% of the total diagnosed prevalent cases of NCFB in 2024.
In 2024, there were approximately 262,000 mild, 426,000 moderate, and 362,000 severe cases of NCFB in the 7MM.
In 2024, Japan accounted for approximately 99,000 diagnosed prevalent cases of NCFB and approximately 100 diagnosed prevalent cases of cystic fibrosis bronchiectasis in the 7MM.
DelveInsight’s “Bronchiectasis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of bronchiectasis historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Bronchiectasis: Disease Understanding
Bronchiectasis Overview, and Diagnosis
Bronchiectasis is a chronic lung disease marked by permanent dilation of the bronchi and bronchioles due to repeated infection and inflammation, leading to structural damage. It often begins with airway narrowing from infection, and impaired mucociliary clearance causes mucus retention, promoting recurrent infections.
Bronchiectasis symptoms vary by individual but commonly include a chronic cough with sputum (ranging in volume and color), breathlessness, fatigue due to energy spent fighting infections and breathing, chest discomfort (pain, tightness, or fullness), and frequent chest infections or exacerbations where symptoms worsen.
Diagnosis of bronchiectasis involves a combination of imaging, clinical evaluation, and other tests to assess lung damage and identify any underlying causes. Chest CT scan is the primary diagnostic tool. Additional tests like sputum culture, blood work, lung function tests, and genetic screening may be used to investigate contributing conditions. In cases where symptoms persist despite treatment, bronchoscopy may be performed for further airway examination.
Bronchiectasis Epidemiology
The Bronchiectasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of NCFB, gender-specific diagnosed prevalent cases of NCFB, severity-specific diagnosed prevalent cases of NCFB, etiology-specific diagnosed prevalent cases of NCFB, microbiology of NCFB patients, total diagnosed prevalent cases of cystic fibrosis bronchiectasis, gender-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis, age-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis, and microbiology of cystic fibrosis bronchiectasis patients in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
In 2024, among the EU4 and the UK, the UK had the highest number of diagnosed prevalent cases of NCFB, with nearly 230,000 cases, followed by Spain with approximately 152,000 cases. In contrast, France had the lowest diagnosed prevalent population, with around 38,000 cases.
In 2024, there were approximately 32,000 children and 47,000 adults diagnosed with cystic fibrosis bronchiectasis in the 7MM.
In 2024, there were approximately 90,000 mild, 160,000 moderate, and 138,000 severe cases of NCFB in the US.
In 2024, out of the diagnosed prevalent cases of Cystic Fibrosis Bronchiectasis in the US, ~11,000 were infected with P. aeruginosa, ~ 25,000 with S. aureus, and ~ 6,000 with other pathogens.
In 2024, the gender-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis in the US were approximately 22,000 in males and 20,000 in females.
Scope of the Report
The report covers a segment of an executive summary, and a descriptive overview of bronchiectasis explaining its causes, signs and symptoms, pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Bronchiectasis Report Insights
Patient Population
Country-wise Epidemiology Distribution
Bronchiectasis Report Key Strengths
Ten-year Forecast
The 7MM Coverage
Bronchiectasis Epidemiology Segmentation
Bronchiectasis Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of Bronchiectasis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to bronchiectasis?
What is the historical and forecasted bronchiectasis patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of bronchiectasis?
Which clinical factors will affect bronchiectasis?
Which factors will affect the increase in the diagnosis of bronchiectasis?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in bronchiectasis cases in varying geographies over the coming years.
A detailed overview of total diagnosed prevalent cases of NCFB, gender-specific cases of NCFB, severity-specific cases of NCFB, etiology-specific cases of NCFB, microbiology of NCFB patients, total diagnosed prevalent cases of cystic fibrosis bronchiectasis, gender-specific cases of cystic fibrosis bronchiectasis, age-specific cases of cystic fibrosis bronchiectasis, and microbiology of cystic fibrosis bronchiectasis is included.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Bronchiectasis is a chronic lung disease marked by the permanent widening of the bronchial airways and impaired mucociliary function, resulting from repeated infections that promote bacterial invasion and mucus build up in the bronchial tree.
Bronchiectasis may develop due to various underlying lung-related conditions, including airway obstructions, cystic fibrosis, autoimmune and immunodeficiency disorders, chronic obstructive pulmonary disease (COPD), ciliary dysfunction, inflammatory bowel disease, allergic bronchopulmonary aspergillosis, chronic aspiration, and recurrent infections such as pneumonia, tuberculosis, pertussis, and fungal diseases.
In 2024, there were approximately 1,050,000 total diagnosed prevalent cases of non-cystic fibrosis bronchiectasis (NCFB) in the 7MM.
In 2024, there were approximately 79,000 total diagnosed prevalent cases of Cystic Fibrosis Bronchiectasis in the 7MM.
Among the 7MM, the US accounted for approximately 37%, EU4, and the UK for nearly 54%, and Japan for around 9% of the total diagnosed prevalent cases of NCFB in 2024.
In 2024, there were approximately 262,000 mild, 426,000 moderate, and 362,000 severe cases of NCFB in the 7MM.
In 2024, Japan accounted for approximately 99,000 diagnosed prevalent cases of NCFB and approximately 100 diagnosed prevalent cases of cystic fibrosis bronchiectasis in the 7MM.
DelveInsight’s “Bronchiectasis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of bronchiectasis historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Bronchiectasis: Disease Understanding
Bronchiectasis Overview, and Diagnosis
Bronchiectasis is a chronic lung disease marked by permanent dilation of the bronchi and bronchioles due to repeated infection and inflammation, leading to structural damage. It often begins with airway narrowing from infection, and impaired mucociliary clearance causes mucus retention, promoting recurrent infections.
Bronchiectasis symptoms vary by individual but commonly include a chronic cough with sputum (ranging in volume and color), breathlessness, fatigue due to energy spent fighting infections and breathing, chest discomfort (pain, tightness, or fullness), and frequent chest infections or exacerbations where symptoms worsen.
Diagnosis of bronchiectasis involves a combination of imaging, clinical evaluation, and other tests to assess lung damage and identify any underlying causes. Chest CT scan is the primary diagnostic tool. Additional tests like sputum culture, blood work, lung function tests, and genetic screening may be used to investigate contributing conditions. In cases where symptoms persist despite treatment, bronchoscopy may be performed for further airway examination.
Bronchiectasis Epidemiology
The Bronchiectasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of NCFB, gender-specific diagnosed prevalent cases of NCFB, severity-specific diagnosed prevalent cases of NCFB, etiology-specific diagnosed prevalent cases of NCFB, microbiology of NCFB patients, total diagnosed prevalent cases of cystic fibrosis bronchiectasis, gender-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis, age-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis, and microbiology of cystic fibrosis bronchiectasis patients in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
In 2024, among the EU4 and the UK, the UK had the highest number of diagnosed prevalent cases of NCFB, with nearly 230,000 cases, followed by Spain with approximately 152,000 cases. In contrast, France had the lowest diagnosed prevalent population, with around 38,000 cases.
In 2024, there were approximately 32,000 children and 47,000 adults diagnosed with cystic fibrosis bronchiectasis in the 7MM.
In 2024, there were approximately 90,000 mild, 160,000 moderate, and 138,000 severe cases of NCFB in the US.
In 2024, out of the diagnosed prevalent cases of Cystic Fibrosis Bronchiectasis in the US, ~11,000 were infected with P. aeruginosa, ~ 25,000 with S. aureus, and ~ 6,000 with other pathogens.
In 2024, the gender-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis in the US were approximately 22,000 in males and 20,000 in females.
Scope of the Report
The report covers a segment of an executive summary, and a descriptive overview of bronchiectasis explaining its causes, signs and symptoms, pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Bronchiectasis Report Insights
Patient Population
Country-wise Epidemiology Distribution
Bronchiectasis Report Key Strengths
Ten-year Forecast
The 7MM Coverage
Bronchiectasis Epidemiology Segmentation
Bronchiectasis Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of Bronchiectasis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to bronchiectasis?
What is the historical and forecasted bronchiectasis patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of bronchiectasis?
Which clinical factors will affect bronchiectasis?
Which factors will affect the increase in the diagnosis of bronchiectasis?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in bronchiectasis cases in varying geographies over the coming years.
A detailed overview of total diagnosed prevalent cases of NCFB, gender-specific cases of NCFB, severity-specific cases of NCFB, etiology-specific cases of NCFB, microbiology of NCFB patients, total diagnosed prevalent cases of cystic fibrosis bronchiectasis, gender-specific cases of cystic fibrosis bronchiectasis, age-specific cases of cystic fibrosis bronchiectasis, and microbiology of cystic fibrosis bronchiectasis is included.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
101 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Bronchiectasis Patient Overview at a Glance
- 3.1. Patient Share Distribution (%) in the 7MM in 2024
- 3.2. Patient Share Distribution (%) in the 7MM in 2034
- 4. Executive Summary
- 5. Epidemiology Forecast Methodology
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Signs and Symptoms
- 6.3. Causes
- 6.4. Diagnosis and Differential Diagnosis
- 6.4.1. Diagnostic Algorithm
- 6.4.2. Differential Diagnosis
- 6.4.3. Diagnostic Guidelines
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Diagnosed Prevalent Cases of NCFB in the 7MM
- 7.4. Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the 7MM
- 7.5. The United States
- 7.5.1. Total Diagnosed Prevalent Cases of NCFB in the US
- 7.5.2. Gender-specific Diagnosed Prevalent Cases of NCFB in the US
- 7.5.3. Severity-specific Diagnosed Prevalent Cases of NCFB in the US
- 7.5.4. Etiology-specific Diagnosed Prevalent Cases of NCFB in the US
- 7.5.5. Microbiology of NCFB Patients in the US
- 7.5.6. Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US
- 7.5.7. Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US
- 7.5.8. Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US
- 7.5.9. Microbiology of Cystic Fibrosis Bronchiectasis Patients in the US
- 7.6. EU4 and the UK
- 7.6.1. Total Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 7.6.2. Gender-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 7.6.3. Severity-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 7.6.4. Etiology-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 7.6.5. Microbiology of NCFB Patients in EU4 and the UK
- 7.6.6. Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in EU4 and the UK
- 7.6.7. Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in EU4 and the UK
- 7.6.8. Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in EU4 and the UK
- 7.6.9. Microbiology of Cystic Fibrosis Bronchiectasis Patients in EU4 and the UK
- 7.7. Japan
- 7.7.1. Total Diagnosed Prevalent Cases of NCFB in Japan
- 7.7.2. Gender-specific Diagnosed Prevalent Cases of NCFB in Japan
- 7.7.3. Severity-specific Diagnosed Prevalent Cases of NCFB in Japan
- 7.7.4. Etiology-specific Diagnosed Prevalent Cases of NCFB in Japan
- 7.7.5. Microbiology of NCFB Patients in Japan
- 7.7.6. Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan
- 7.7.7. Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan
- 7.7.8. Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan
- 7.7.9. Microbiology of Cystic Fibrosis Bronchiectasis Patients in Japan
- 8. Appendix
- 8.1. Acronyms and Abbreviations
- 8.2. Bibliography
- 8.3. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
